RNS Number:5265Q
Xenova Group PLC
03 October 2003



           Xenova Group plc Offer For KS Biomedix Holdings Plc Update

   Not for release, publication or distribution in or into the United States,
                           Canada, Australia or Japan

                  Xenova Group plc ("Xenova"), 3 October 2003

  RECOMMENDED OFFER FOR KS BIOMEDIX HOLDINGS PLC ("KS BIOMEDIX") ("THE OFFER")

                        DISPATCH OF SECTION 429 NOTICES

The Offer became unconditional in all respects on 15 September 2003.  As at 3pm
on 2 October 2003,  Xenova had received valid acceptances in respect of the
Offer for KS Biomedix representing 93.36 per cent. of the issued ordinary share
capital of KS Biomedix. As valid acceptances of the Offer have been received in
respect of over 90 per cent. of the KS Biomedix Shares to which the Offer
relates, Xenova announces that statutory notices were dispatched today pursuant
to section 429 of the Companies Act 1985 to KS Biomedix Shareholders who have
not accepted the Offer to acquire compulsorily all the KS Biomedix Shares in
respect of which valid acceptances of the Offer have not been received.  The
compulsory acquisition procedure is expected to be concluded on or shortly after
14 November 2003.



The Offer remains open for acceptance until 14 November 2003. KS Biomedix
Shareholders who have not yet accepted the Offer are reminded to complete and
return their Form of Acceptance in accordance with the instructions contained
therein as soon as possible.



Terms defined in the Offer Document dated 14 August 2003 have the same meaning
in this announcement.



Enquiries:
David Oxlade, Xenova                                    01753 706 600
David Rasouly, Nomura                                   020 7521 2000
David Yates, Financial Dynamics                         020 7831 3113



Nomura is acting exclusively for Xenova in connection with the Offer and is not
advising any other person or treating any other person as its client in relation
thereto and will not be responsible to anyone other than Xenova for providing
the protections afforded to clients of Nomura or for providing advice in
relation to the Offer or the New Xenova Shares.



This announcement does not constitute an offer or an invitation to purchase any
securities.



This announcement does not constitute an offer of securities for sale in the
United States and the New Xenova Shares have not been, and will not be,
registered under the United States Securities Act of 1933, as amended, nor under
any laws of any state of the United States, and the relevant clearances have not
been and will not be obtained from the relevant authorities in Canada, Australia
or Japan.  Accordingly, unless an exemption under any applicable laws is
available, the New Xenova Shares may not be offered, sold, resold, delivered or
transferred directly or indirectly, in or into the United States, Canada,
Australia or Japan or any other country outside the United Kingdom where such
distribution may otherwise lead to a breach of law or other regulatory
requirement, or to or for the benefit of US Persons.



The Offer referred to in this announcement is not being made, directly or
indirectly, in or into, or by use of the mails of or by any means of
instrumentality (including, without limitation, facsimile transmissions, telex,
telephone or internet) or interstate or foreign commerce of, or any facilities
of a securities exchange of, the United States, nor is it being made, directly
or indirectly, to or for the benefit of US Persons, nor is it being made,
directly or indirectly, in or into Canada, Australia, or Japan unless an
exemption under any applicable laws is available.  This announcement is not
being, and it must not be, mailed or otherwise forwarded, distributed or sent
in, or into the United States, Canada, Australia or Japan and doing so may
render invalid any purported acceptance of the Offer.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

OUPUUGQWUUPWGAW